Literature DB >> 1767242

[Efficacy and tolerance of aniracetam in elderly patients with primary or secondary mental deterioration].

V Canonico1, L Forgione, C Paoletti, A Casini, C V Colonna, M Bertini, R Acito, F Rengo.   

Abstract

The study was carried out on 60 patients (mean age 69.9 +/- 10.3 years) suffering from slight-moderate brain pathology primary or secondary to vascular forms. Patients were treated with 1500 mg/day per os of Aniracetam or placebo. Drug efficiency evaluation was performed utilizing the following psychometric tests: Blessed Scale, figures repetition test, Benton test, Corsi test, Rey test, Pieron test, phrases construction test, verbal fluency test. They were carried out during basal visit after two and four month treatment. In Aniracetam treated group the score showed a significant improving during the first and second control. In placebo treated group no change statistically considerable happened in any test. Aniracetam has proved to be a useful drug in slight-moderate brain decay treatment of the elderly.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1767242

Source DB:  PubMed          Journal:  Riv Neurol        ISSN: 0035-6344


  3 in total

Review 1.  Aniracetam. An overview of its pharmacodynamic and pharmacokinetic properties, and a review of its therapeutic potential in senile cognitive disorders.

Authors:  C R Lee; P Benfield
Journal:  Drugs Aging       Date:  1994-03       Impact factor: 3.923

Review 2.  Piracetam and piracetam-like drugs: from basic science to novel clinical applications to CNS disorders.

Authors:  Andrei G Malykh; M Reza Sadaie
Journal:  Drugs       Date:  2010-02-12       Impact factor: 9.546

3.  Acupuncture promotes functional recovery after cerebral hemorrhage by upregulating neurotrophic factor expression.

Authors:  Dan Li; Qiu-Xin Chen; Wei Zou; Xiao-Wei Sun; Xue-Ping Yu; Xiao-Hong Dai; Wei Teng
Journal:  Neural Regen Res       Date:  2020-08       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.